Description
Emorivir 200Mg - Anti-COVID Generic Drug Molnupiravir
Molnupiravir is the
world’s first oral pill to treat symptomatic COVID-19 which was approved
by the UK’s Medicines and Healthcare products Regulatory Agency on 4
November 2021. Molnupiravir is originally developed by the US based
pharma major Merck, Sharp & Dohme (MSD) and Ridgeback
Biotherapeutics. Beximco Pharma’s branded generic version of
molnupiravir will be marketed as Emorivir. Availability of generic
molnupiravir will help broaden access and affordability of COVID-19
treatment, especially in low and middle income countries where access to
vaccines has been limited.
Available to order now
Inbox us or
Mobile / WhatsApp : +44 7887 477007
Email : info@premiameds.com
